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ABSTRACT Enterotoxigenic Escherichia coli (ETEC), a heterogeneous diarrheal patho-
var deﬁned by production of heat-labile (LT) and/or heat-stable (ST) toxins, causes
substantial morbidity among young children in the developing world. Studies dem-
onstrating a major burden of ST-producing ETEC have focused interest on ST toxoids
for ETEC vaccines. We examined fundamental aspects of ST biology using ETEC
strain H10407, which carries estH and estP genes encoding STh and STp, respec-
tively, in addition to eltAB genes responsible for LT. Here, we found that deletion of
estH signiﬁcantly diminished cyclic GMP (cGMP) activation in target epithelia, while
deletion of estP had a surprisingly modest impact, and a dual estH estP mutant was
not appreciably different from the estH mutant. However, we noted that either STh
or STp recombinant peptides stimulated cGMP production and that the loss of estP
was compensated by enhanced estH transcription. We also found that the TolC ef-
ﬂux protein was essential for toxin secretion and delivery, providing a potential ave-
nue for efﬂux inhibitors in treatment of acute diarrheal illness. In addition, we dem-
onstrated that the EtpA adhesin is required for optimal delivery of ST and that
antibodies against either the adhesin or STh signiﬁcantly impaired toxin delivery and
cGMP activation in target T84 cells. Finally, we used FLAG epitope fusions to demon-
strate that the STh propeptide sequence is secreted by ETEC, potentially providing
additional epitopes for antibody neutralization. These studies collectively extend our
understanding of ETEC pathogenesis and potentially inform additional avenues to
mitigate disease by these common diarrheal pathogens.
KEYWORDS diarrhea, enterotoxigenic, heat-stable toxin, pathogenesis, toxoids,
vaccines
Diarrheal illnesses in low-income countries continue to cause substantial morbidityand remain one of the leading causes of death in young children under the age
of 5 years in developing countries. Among the bacterial causes of diarrheal illness,
enterotoxigenic Escherichia coli strains (ETEC) are commonly linked to more-severe
forms of illness in young children (1). These organisms are perennially the most
common cause of diarrhea in those who travel to areas of endemicity where sanitation
is poor (2, 3); however, they have been identiﬁed repeatedly as the etiology of diarrheal
outbreaks and sporadic cases of illness in industrialized countries, including the United
States (4–8).
Acute clinical presentations of ETEC infection may range from mild self-limited
illness to severe choleralike diarrhea (9–11). In addition, ETEC and other diarrheal
pathogens have been linked to pernicious sequelae, including malnutrition, growth
stunting, and impaired cognitive development (12). Presently, there are no vaccines to
protect against these common infections. ETEC strains are a genetically (13) and
serotypically (14) diverse pathovar of E. coli deﬁned by the production of heat-labile (LT)
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and/or heat-stable (ST) enterotoxins that activate production of host cyclic nucleotides
to alter intestinal salt and water transport that culminate in net ﬂuid losses and
secretory diarrhea.
Heat-stable toxins are synthesized as 72-amino-acid proteins consisting of a signal
peptide, a propeptide, and a carboxy-terminal region of 18 to 19 amino acids, which
forms the mature active enterotoxin (15). Two enterotoxins cause disease in humans:
STp (ST1a), 18 amino acids, and STh (ST1b), 19 amino acids. Both of the mature toxins
contain a total of six cysteine residues that form three intramolecular disulﬁde bonds
(16). Their overall structure is shared with two similar mammalian peptides, guanylin
and uroguanylin. Each of the bacterial and mammalian peptides binds to guanylate
cyclase C (17, 18), leading to increases in intracellular cyclic GMP (cGMP) (19). Increases
in cGMP result in activation of protein kinases that phosphorylate and activate the
cystic ﬁbrosis transmembrane regulatory (CFTR) channel and inhibit sodium-hydrogen
ion exchange via sodium/hydrogen exchanger 3 (NHE3) (20). These effects lead to a net
loss of salt and water into the intestinal lumen with ensuing watery diarrhea.
Bacteria producing any of the toxins LT, STh, or STp have been linked to diarrheal
illness in humans (21–24), and recent studies suggest that ST-producing ETEC is
commonly represented among the pathogens that cause severe diarrheal illness
among young children in low-income countries, leading to substantial interest in the
development of a vaccine that incorporates ST toxoids (25).
Enterotoxigenic E. coli strain H10407, originally isolated from a case of severe
choleralike diarrheal illness in Bangladesh, is to date the most extensively characterized
isolate of this pathovar. Interestingly, this isolate encodes all three canonical entero-
toxins associated with ETEC diarrheal illness in humans (26, 27), with the gene for STh
on the largest (94,797-bp) virulence plasmid p948 (NCBI GenBank accession number
NC_017724.1) and the genes for both LT and STp on a 66,681-bp plasmid, p666 (NCBI
GenBank accession number NC_017722.1) (28). In addition, H10407 encodes a copy of
the ST-like EAST1 peptide (29) on the large p948 plasmid (30). H10407 is frequently
used as the challenge strain in controlled human infection models to test candidate
vaccines. Therefore, we set out to examine the relative contribution of STh and STp to
the accumulation of cGMP in host epithelia by H10407 and the ability of anti-ST and
antiadhesin antibodies to mitigate effective toxin delivery by the bacteria.
RESULTS
Contributions of STh, STp, and EAST1 to activation of cGMP in target epithelial
cells. Understanding the individual contributions of ST and ST-like molecules of ETEC
is relevant to development and testing of toxin neutralization strategies. H10407
encodes three peptides with the potential to activate cGMP in target intestinal epithe-
lial cells: STh, STp, and EAST1, a heat-stable toxin originally identiﬁed in enteroaggre-
gative E. coli (29). STh is encoded by the estH gene on the large, 94,797-bp plasmid
p948 (NCBI GenBank accession NC_017724.1). The astA gene, which encodes the EAST1
peptide (30), is embedded within an IS1414 insertion sequence (31) and is also located
on the p948 plasmid immediately downstream from the etpBAC adhesin locus (28, 32).
STp is encoded by the estP gene on a second, 66-kb virulence plasmid (NCBI GenBank
accession number FN649417.1) in H10407.
We found that deletion of estH resulted in appreciable decreases in cGMP produc-
tion at or near background levels of cGMP production by uninfected cells and that
complementation of estH in trans restored activation of this cyclic nucleotide (Fig. 1A).
In contrast, the estPmutant was not appreciably different from the wild-type strain, and
the introduction of the estPmutation to the estH strain did not yield further measurable
decreases in cGMP production by target epithelial cells. Similar results were obtained
at various multiplicities of infection (MOIs) (Fig. 1B), suggesting that this was not related
to a spurious inoculum effect. In addition, infection of small intestinal enteroids
demonstrated that while deletion of estH alone resulted in a substantial decrease in the
production of cGMP in target epithelia to background levels, deletion of estP had no
demonstrable effect on cyclic nucleotide production (Fig. 1C). However, we found that
Zhu et al. Infection and Immunity












in distinct contrast to an A14Q mutant STh peptide (25), the target T84 cells did
respond to glutathione S transferase (GST) fusions to either STh or STp (Fig. 1D) and
that estP complementation of the estH estP dual deletion mutant in trans was sufﬁcient
to completely restore activation of cGMP to wild-type levels (Fig. 1E), clearly suggesting
that enterocytes have the capacity to respond to either peptide. These results sug-
gested that deletion of estP results in a compensatory increase in estH transcription
and/or secretion of the encoded peptide. Interestingly, we found that relative to what
was seen in the wild-type strain, estH transcription was signiﬁcantly increased in the












































































































































































































FIG 1 Relative contributions of STh and STp to cGMP production in target epithelia. (A) cGMP production in T84 target epithelial cells following infection with
wild-type estH, the complemented estH mutant estH(pQL231), the estP mutant, the complemented estP mutant estP(pQL230), and the estH estP dual deletion
mutant. ø, uninfected cells. Data represent the combined results of two experimental replicates with each data point representing a technical replicate. (B) cGMP
production in T84 cells at various multiplicities of infection with H10407 (wt), the estH or estP mutant, or the estH estP dual deletion mutant (n  3 technical
replicates; shown are mean values  standard errors of the means [SEM]). (C) cGMP production in small intestinal enteroids following infection with the wild
type (wt) , the estH or estP mutant, or the estH estP dual deletion mutant. (D) cGMP production in T84 cells following addition of puriﬁed GST, GST-STh, or
GST-STp fusions. Numbers on the x axis represent ﬁnal concentrations of protein in micrograms per milliliter. ø, untreated cells. Data include three technical
replicates where geometric means are represented as bars. In panels A, C, and D, bars represent geometric means, with statistical comparisons by analysis of
variance (ANOVA) (Kruskal-Wallis); *, P  0.05; **, P  0.01. (E) Complementation of the estH estP mutant with estP in trans (jf3626) restores wild-type levels of
toxin activity following infection of T84 cells (bars represent results for 3 technical replicates SEM). (F) Transcription of estH gene in wild-type and estPmutant
bacteria. Individual symbols represent 6 technical replicates combined from two independent experiments. Horizonal lines represent geometric means of
expression relative to the wild type (H10407); **, P  0.002 by Mann-Whitney (two-tailed) nonparametric comparison. (G) Transcription of estP gene in estH
mutant bacteria relative to the wild type. The estP-complemented estH estP mutant, jf3626, is shown as a positive transcription control (***, P  0.0002 by
ANOVA, Kruskal-Wallis testing). (H) Transcription of genes encoding ST toxins STh (estH), STp (estP), and TolC. Data are normalized relative to the arcA
housekeeping gene and represent the ratio of transcripts attached to planktonic bacteria at 30 and 90 min after infection of monolayers. Whisker plots represent
the range of data obtained over six replicates from two independent experiments. Horizontal lines represent mean values. Data for each group represent mean
of 3 replicates  SEM.
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increased (Fig. 1G). Collectively, these results suggest that both ST peptides likely act in
conjunction with heat-labile toxin to cause the diarrheal illness associated with the
H10407 strain, but the molecular details governing transcriptional regulation of toxin
production have not been completely elucidated.
Because we previously demonstrated that a number of virulence factors are tran-
scriptionally modulated by ETEC pathogen-host cell interaction (33) we also examined
transcription of both ST toxin genes and tolC, which encodes the putative export
channel for ST. Interestingly, we found that in contrast to estH, estP transcription was
signiﬁcantly inﬂuenced by bacterial cell contact, with transcription of the gene encod-
ing STp enhanced by bacterial adhesion, as was the tolC gene (Fig. 1H). These data
suggest that similar to LT, the secretion and delivery of one or both of the STh and
STp heat-stable toxins are likely highly orchestrated by contact with the intestinal
epithelia.
In addition to STh and STp, earlier studies demonstrated that ETEC strains, including
H10407 (31), also encode EAST, a heat-stable toxin originally identiﬁed in enteroaggre-
gative E. coli (29, 31). Although the structures of the mature EAST and STh peptides are
similar, there is only 37% identity (7/19 amino acids) between the two molecules (29),
a ﬁnding that could impact the rational design of toxoids if EAST contributes to ETEC
diarrheal illness. However, induction of cGMP in monolayers infected with a strain
carrying an isogenic mutation of the astA gene, encoding EAST on the large p948
virulence plasmid of H10407 (3.8  0.42 pmol/ml), was not signiﬁcantly different from
that of the wild-type parent (4.0  0.35 pmol/ml), while deletion of both estP and estH
resulted in complete abrogation of cGMP production (0.52  0.06 pmol/ml), ﬁndings
that suggest that EAST may not contribute signiﬁcantly to diarrheal illness caused by
this particular ETEC isolate.
TolC is required for effective ETEC secretion of STh and STp. The precise
mechanism for secretion of heat-stable toxins from ETEC strains associated with disease
in humans is presently uncertain. Prior studies of heat-stable toxin investigated the
secretion of STb (ST-II) (34) or STp (STIa) (35) from laboratory strains of E. coli containing
recombinant expression plasmids. While both studies suggested that the outer mem-
brane protein TolC is involved in secreting these toxins from the recombinant E. coli
background, there are conﬂicting data regarding the involvement of the STb (STII) toxin
in human disease (36, 37), and unlike the STh and STp toxins, STb does not bind to
guanylate cyclase C. Similarly, to our knowledge, there has been no veriﬁcation of the
role of tolC in mediating the secretion of either of the ST1 toxins (STh and STp) from
strains of ETEC isolated from humans. Therefore, to verify the importance of TolC in
secretion of both STh and STp from ETEC strains that cause human illness, we
constructed an isogenic tolC mutant in the ETEC H10407 strain and tested the ability of
the mutant bacteria to deliver ST to target epithelial cells.
We found that mutants lacking tolC were devoid of detectable toxin in culture super-
natants (Fig. 2A) and were markedly deﬁcient in their ability to deliver ST toxins to epithelial
monolayers, as we observed only background levels of cGMP production following infec-
tion with the tolCmutant strain, and complementation with tolC in trans restored the ability
of the bacteria to provoke a cGMP response in targeted cells (Fig. 2B).
Optimal delivery of ST requires the EtpA adhesin. We have previously demon-
strated that intimate interaction of ETEC with intestinal epithelial cells is essential for
efﬁcient delivery of heat-labile toxin to intestinal epithelial cells (38). Moreover, delivery of
LT requires the concerted action of several ETEC adhesins with different receptor speciﬁc-
ities (39, 40, 52) including EtpA, a plasmid-encoded secreted adhesin (32) that serves as a
molecular bridge between bacteria and intestinal epithelial cells (42). EtpA is expressed by
a diverse population of ETEC isolates (43), is recognized during the course of infection (44),
and is a protective antigen in preclinical models of ETEC infection (40, 45, 46).
Because we are exploring the role of EtpA as a protective immunogen (47) and
ST-producing ETEC strains have predominated in recent epidemiologic studies (1, 48),
we set out to examine the dependence of ST delivery on EtpA-mediated bacterial
Zhu et al. Infection and Immunity












adhesion by comparing cGMP activation of target intestinal epithelial cells infected
with wild-type ETEC to that in cells infected with an isogenic etpAmutant. These studies
demonstrated that cGMP activation in target epithelia by wild-type bacteria was
signiﬁcantly accelerated relative to that seen with the etpA mutant (Fig. 3), suggesting
that efﬁcient delivery of these small peptides also requires effective bacterium-host
interactions.
Similarly, we found that antibodies directed against either the EtpA adhesin mole-
cule or STh signiﬁcantly inhibited the delivery of heat-stable toxins to target cells (Fig.
4). Although we were not able to demonstrate that the combination of these antibodies
was synergistic, these data provide additional support to the concept that EtpA could
be useful as a target to engender coverage against a wide variety of ETEC isolates that
produce heat-stable and/or heat-labile enterotoxins (43, 49).
Delivery and secretion of epitope-tagged STh. Understanding the nature of ST
secretion and its delivery to epithelial receptors could be relevant to an informed
development of ST toxoid molecules. STh is synthesized as a 72-amino-acid molecule
that includes a 19-amino-acid signal peptide, followed by a 34-amino-acid propeptide
and a mature ST molecule of 19 amino acids. Although most attempts to develop ST
toxoids have targeted the mature peptides (16, 25), there are earlier but conﬂicting data
regarding the precise form of ST that is secreted into the extracellular milieu (15, 50),
with some data suggesting that the propeptide may be exported with subsequent
processing to the mature peptide outside the bacteria (51). To investigate the potential



















































FIG 2 Role of tolC in ST secretion and delivery to target epithelial cells. (A) Immunoblot detection of ST
toxins in culture supernatants of the wild-type H10407 strain, tolC mutant, or estH estP dual deletion
mutant following immunoprecipitation of culture supernatants with afﬁnity-puriﬁed anti-STh antibodies
(IP -STh). BSA and GST-STh fusion are shown as negative and positive controls, respectively. (B) cGMP
production by T84 target epithelial cells following infection with wild-type (wt) ETEC strain H10407 (STh,
STp), the tolC mutant, the vector-complemented mutant (pBAD-Myc-HisB) or the tolC-complemented
mutant (pZY008). Data shown represent the combined results of two experimental replicates. Individual
data points represent technical replicates, and bars indicate the geometric mean values, obtained in the
presence () of phosphodiesterase inhibitors (PDE-I). Statistical comparisons by ANOVA (Kruskal-Wallis):
*, P  0.05.
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terminal end of the propeptide region (FLAG3-pro-STh) of STh and compared the
export and delivery of the resulting peptides to those of carboxy-terminal fusions to the
mature peptide (pro-STh-FLAG3) (Fig. 5).
We were able to recover either the amino-terminal or carboxy-terminal FLAG-tagged
molecules from culture supernatants of estH estP mutant ETEC transformed with the
pSTh-FLAG3 or pFLAG3-STh plasmids, respectively (Fig. 5a). Both molecules appeared to
yield functional ST mature peptides, as either plasmid was sufﬁcient to complement the
ability of the estH estP mutant to activate cGMP in target epithelial cells (Fig. 5b).
Likewise, we were able to demonstrate binding of FLAG-epitope-tagged molecules to
target epithelial cells following infection with either of the complemented strains (Fig.
5c and d). Collectively, these data appear to reafﬁrm earlier observations of STh (51),
suggesting that both the mature form (19 amino acids) of the peptide and the
extended pro-STh (53 amino acids) may be found outside the bacteria.
DISCUSSION
Because of the signiﬁcant global burden of diarrheal illness caused by ETEC, these























FIG 3 The EtpA adhesin is required for optimal delivery of heat-stable toxins. Shown are comparisons of
cGMP activation in target T84 intestinal epithelial cells following infection with wild-type ETEC H10407
or the etpA mutant (n  4 replicates), or the estH estP dual deletion mutant and uninfected monolayers
(n 3). Dashed lines in each group connect geometric mean values obtained at 30 and 60 min following




































FIG 4 Antitoxin and antiadhesin antibodies inhibit heat-stable toxin delivery. Shown are monolayers
infected with the dual heat-stable toxin mutant (estH estP), wild-type H10407, or uninfected control
monolayers (ø). Dotted horizontal lines for each group represent geometric means. *, P 0.028 by Mann
Whitney two-tailed nonparametric comparisons. Both anti-STh and anti-EtpA antibodies were afﬁnity
puriﬁed and cross adsorbed and used at ﬁnal dilution of 1:25.
Zhu et al. Infection and Immunity












as a cause of severe diarrheal illness more than 4 decades ago. Currently, there is no
vaccine available that affords broad-based protection against ETEC, in part due to the
substantial antigenic diversity within the pathovar and limited mechanistic insight into
immunologic correlates of the protection that appears to follow early infections among
young children in areas of endemicity. Moreover, many features of the molecular
pathogenesis of these common pathogens have not been explored in sufﬁcient detail
to inform vaccine development.
Because ST-producing ETEC isolates comprise a large proportion of strains associ-
ated with symptomatic diarrheal illness (1), we investigated the molecular contributions
of the known heat-stable toxins, their proposed secretion apparatus, and bacterial
adhesion to toxin delivery. The present studies suggest that efﬁcient delivery of ST
toxins is a complex process that requires the ability to effectively engage host cells and
produce at least transient adhesion afforded by EtpA and other adhesins (52). More-
over, as antibodies directed at either the EtpA adhesin or ST impaired toxin delivery, our
studies provide further support for development of a vaccine platform that combines
ST toxoid (25) and antiadhesin approaches. However, further studies will be needed to
deﬁne an optimal vaccination approach capable of generating sufﬁcient antibodies to
neutralize binding of the small ST peptides to cognate receptors in the small intestine.
Our data provide an important validation of the potential biologic importance of
both STh and STp toxins. While recent large-scale epidemiologic data have highlighted
the importance of ETEC strains producing STh as a cause of moderate to severe diarrhea
in young children (1), subsequent reevaluation of these data has suggested that





























































































































FIG 5 Secretion and delivery of FLAG-epitope-tagged STh. The schematic (top left) depicts the location of the region encoding the 3FLAG peptide relative
to the estH gene. The arrow shows the location of the predicted signal peptide cleavage site which is retained in both constructs. (a) Anti-FLAG and anti-STh
immunoblots of FLAG3-STh and STh-FLAG3 peptides recovered by anti-FLAG immunoprecipitation from culture supernatants of the ETEC estH estP mutant
bearing pFLAG3-STh and pSTh-FLAG3. (b) Complementation of the estP estH mutant strain with pSTh-FLAG3 or pFLAG3-STh restores toxicity upon infection of
T84 cells. (c) Quantitation of FLAG3-tagged ST delivered to epithelial cells by estH estP bacteria complemented with pSTh-FLAG3 or pFLAG3-STh. Values represent
ﬂuorescence intensity per ﬁeld. ****, P  0.0001 by ANOVA (Kruskal-Wallis test). (d) Confocal immunoﬂuorescence images of bacteria expressing pST-FLAG3
(anti-O78, yellow) attached to T84 cells (nuclei, blue) and the distribution of FLAG epitope-tagged toxin (cyan).
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associated with ETEC (48). Indeed, earlier clinical studies demonstrated that while there
were regional differences in the distribution of STp and STh among ETEC isolates, both
peptides were commonly associated with diarrheal illness, and the clinical presenta-
tions attributed to ETEC producing either ST peptide were indistinguishable (24). In
keeping with these observations, we found no difference in the ability of STh or STp
peptides to elicit cGMP production (19) in target epithelia. Although deletion of the
gene encoding STh resulted in lower cGMP production in infected monolayers than
when the estP gene was deleted from the ETEC H10407 strain, we discovered a
compensatory increase in transcription of estH in the estP mutant. Collectively, there-
fore, our results suggest that both peptides likely contribute to diarrheal illness caused
by H10407. Indeed, deletion of the tolC gene, which encodes the membrane trans-
porter for both peptides, resulted in complete abrogation of cGMP activation in target
epithelial cells, similar to deletion of both the estH and estP toxin genes from H10407.
Earlier studies also noted that many ETEC strains, including H10407, bear copies of
an insertion sequence (31) that encompasses the astA gene encoding EAST1 (30), a
cGMP-activating peptide structurally similar to ST1 that was originally identiﬁed as a
heat-stable enterotoxin in enteroaggregative E. coli (29). However, we saw similar
increases in cGMP production by target epithelial cells following infection with the astA
mutant and wild-type ETEC. We cannot rule out the possibility of EAST1 expression
from additional copies of astA not residing on the large, p948 virulence plasmid or that
EAST1 is not optimally expressed in vitro. However, the complete absence of a cGMP
response in cells infected with the STh/STp deletion mutant might alternatively suggest
that EAST1 does not contribute to ETEC virulence and that further toxoid vaccine
development can simply focus on engendering neutralizing antibody responses to the
established ST and LT enterotoxins.
The reafﬁrmation of TolC as a key mechanism for export of ST1 toxins could be
relevant to the management of diarrheal illness. The rapid emergence of multidrug
resistance in the Enterobacteriaceae that is in part dependent on drug efﬂux through
TolC has stimulated interest in efﬂux inhibitors to enhance the potency of available
antimicrobial agents (53–55). Theoretically, these inhibitors could offer novel therapeu-
tic agents for treatment of ETEC.
Our studies also revisit the concept that the larger propeptide form of STh may be
exported by the bacteria, and the data presented here are consistent with prior
observations suggesting that some processing of the propeptide occurs outside the
bacteria (15, 51). Further study will be needed, however, to determine whether the
propeptide sequence contributes to immunologic recognition of ST following infection
and whether these larger molecules might be exploited in the development of im-
proved toxoids to neutralize ST.
MATERIALS AND METHODS
Bacterial strains and growth conditions. Bacterial strains used are listed in Table 1. For general
purposes, ETEC bacteria were grown in lysogeny broth at 37°C overnight from frozen glycerol stocks. To
optimize synthesis and secretion of ST toxin, bacteria were grown in Casamino Acids-yeast extract-
sucrose medium (CAYE-ST) (2% Casamino Acids, 0.6% yeast extract, 43 mM NaCl, 38 mM K2HPO4, 203 mM
MgSO4, 25 mM MnCl2, 18 mM FeCl3, 2% sucrose) at 37°C overnight from frozen glycerol stocks.
Construction of mutants lacking production and secretion of heat-stable toxins. Lambda red
recombinase-mediated recombination (56) was used to disrupt genes encoding heat-stable toxins in
H10407. In brief, we used the primers jf070212.1 and jf070212.2 to amplify the kanamycin (Km) cassette
from pKD13 with a 36-bp overhang sequence from the estH gene and primers jf070212.3 and jf070212.4
to amplify the kanamycin cassette from pKD13 with a 36-bp overhang sequence from the estP gene. The
PCR product was electroporated into competent H10407 containing helper plasmid pKD46 and selected
on LB plates with 50 g/ml kanamycin. Kanamycin-resistant (Kmr) colonies were screened by PCR with
primers jf071612.1 and jf071612.2 for the estH locus and with primers jf071612.3 and k2 for estP. The
deletion mutants were further conﬁrmed by toxin multiplex PCR as previously described (57).
To construct complemented strains, we ampliﬁed the estP gene with primers jf030316.3 and
jf060614.1 for cloning into the XhoI site of pBAD/mycHisA, yielding pQL239; estH was ampliﬁed with
primers jf072414.5 and jf072414.6 and cloned into the EcoRV site of pACYC184 to produce pSMD001. We
also cloned estH and estP genes individually and together in pETDuet-1 at NcoI and EcoRI sites and at
BglII and XhoI sites with primer pairs jf060614.2/jf060614.3 and jf060614.4/jf060614.5, respectively. This
resulted in plasmids pQL230 (estP), pQL231(estH), and pQL238 (estP estH) (Table 1). After conﬁrmation by
Zhu et al. Infection and Immunity












sequencing, the respective plasmids were transformed into the deletion strains, and complementation
was conﬁrmed by PCR.
To generate an ETEC tolC deletion mutant, primers jf110716.44/45 were ﬁrst used to amplify a
ΔtolC732::Kmr fragment from JQ55031 (58). Next, the regions ﬂanking tolC in the H10407 genome were
ampliﬁed with primer pairs jf110716.38/jf110716.43 and jf110716.46/jf110716.39 to amplify 1,027 bp of
upstream sequence and 985 bp of downstream sequence, respectively. The three resulting fragments
were then fused by PCR with primer pairs jf110716.38/jf110716.39, using high-ﬁdelity polymerase
Phusion (Thermo Fisher Scientiﬁc), with denaturing for 2 min at 98°C, followed by 30 cycles of 10 s at
98°C, 30 s at 65°C, and 1.5 min at 72°C and a ﬁnal extension for 10 min at 72°C. The resulting 3,325-bp
amplicon was then introduced into H10407(pKD46) as described above. Kanamycin-resistant, ampicillin-
sensitive colonies were then screened by colony PCR using primer pair jf112016.50/51 ﬂanking the entire
amplicon for a 4,269-bp product and primers jf101716.21/22 speciﬁc to tolC gene (603-bp product).
Primers k2/jf112016.51 (2,024-bp product) were then used to conﬁrm the tolC gene deletion and the Kmr
cassette integration in the H10407 genome. To complement the tolCmutant, the tolC gene was ampliﬁed
from H10407 genomic DNA using primers jf120716.59/jf120716.60, and the plasmid vector backbone
was ampliﬁed from plasmid pBAD/myc-His B using primers jf120716.52/jf120716.53. The recombinant
pYZ008 complementation plasmid was assembled using an adaptation of circular polymerase extension
cloning (CPEC) (59) (30 s of denaturation at 98°C, followed by 20 cycles of 10 s at 98°C, 30 s at 55°C, and
1.5 min at 72°C and a ﬁnal extension for 10 min at 72°C). Following sequence veriﬁcation, pYZ008 or the
TABLE 1 Bacterial strains and plasmids used in this studyd
Strain or
plasmid Description Source or reference(s)
Strains
H10407 Wild-type ETEC strain O78:H11; CFA/1; LT, STh, STp; EtpA 28, 32, 64
jf2656 H10407 derivative with isogenic deletion of estP This study
jf2649 H10407 derivative with isogenic deletion of estH This study
jf2847 H10407 derivative with isogenic deletion of estP and estH This study
jf3038 Deletion of astA on the large p948 virulence plasmid of H10407; Kmr This study
jf3076 jf2656 complemented with pQL230 This study
jf3081 jf2649 complemented with pQL231 This study
JW5503-1 E. coli K-12 in-frame ΔtolC732::Kmr 58
jf4652 H010407 derivative with tolC::Kmr mutation This study
jf4709 jf4652 with pBAD/mycHisB This study
jf4712 jf4652 complemented with pYZ008 This study
jf4644 jf2847 with pFLAG-CTC, Cmr Kmr Ampr This study
jf4648 jf2847 with pFLAG-STh, Cmr Kmr Ampr This study
jf4651 jf2847 with pSTh-FLAG, Cmr Kmr Ampr This study
jf3626 jf2847 with pQL239, Cmr Kmr Ampr This study
AAEC191A Aﬁmbriate E. coli K-12 derivative 61
Plasmids
pBAD/mycHisA pBR322ori; PBAD; Ampr; araC; C-terminal myc epitope tag; arabinose-inducible expression plasmid Invitrogen
pBAD/mycHisB pBR322ori; PBAD; Ampr; araC; C-terminal myc epitope tag; arabinose-inducible expression plasmid Invitrogen
pKD13 oriRSK Tn5 neomycin phosphotransferase (Kmr), FRT, -lactamase (Ampr) 56
pKD46 Lambda red recombinase helper plasmid 56
pQL239 estP cloned into XhoI site of pBAD/myc-HisA in frame with myc-His tags This study
pACYC184 p15Aori, Cmr Tcr 65
pSMD001 estH cloned into EcoRV site of pACYC184 This study
pGPS4 oriRSK Cmr Tcr NEB
pETDuet-1 pBR322ori; lacI; Ampr; IPTG-inducible expression plasmid Novagen
pQL230 estP cloned into BglII and XhoI sites of pETDeut-1 This study
pQL231 estH cloned into NcoI and EcoRI sites of pETDeut-1 This study
pQL238 estP cloned into BglII and XhoI sites and estH cloned into NcoI and EcoRI sites of pETDeut-1 This study
pGEX-4T1 lacIq, Ampr; expression plasmid for N-terminal GST fusions GE Healthcare Life
Sciences
pCW002a 5,047-bp GST-STh expression plasmid, Ampr This study
pCW003b estP cloned into BamHI and EcoRI sites of pGEX This study
pYZ011c 5,047-bp GST-mSTh expression plasmid for mSTh (A14Q), Ampr This study, 25
pYZ008 H10407 tolC cloned into pBAD/mycHisB This study
pFLAG-CTC 5.3-kb plasmid, expressing C-terminal FLAG fusion proteins, Ampr Sigma
pFLAG3-STh 5,609-bp Flag-pro-STh expression plasmid, Ampr This study
pSTh-FLAG3 5,612-bp pro-STh-Flag expression plasmid, Ampr This study
aAddgene accession number 90225 (https://www.addgene.org/90225/).
bAddgene accession number 90226 (https://www.addgene.org/90226/).
cAddgene accession number 110570 (https://www.addgene.org/110570/).
dAbbreviations: Kmr, kanamycin resistance; Tcr, tetracycline resistance; Cmr, chloramphenicol resistance; Ampr, ampicillin resistance; NEB, New England Biolabs; FRT,
FLP recombination target.
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pBAD/myc-His B vector control plasmids were then used to transform the ΔtolC mutant. Complemen-
tation was conﬁrmed by PCR with primers jf101716.21/22.
FLAG-STh fusions. FLAG epitope fusions were constructed to introduce the 3FLAG sequence
between the signal peptide of estH and the beginning of the propeptide-encoding region (on plasmid
pFLAG3-STh) or at the 3= end of estH (on pSTh-FLAG3). The 3FLAG fragment was ﬁrst constructed by
annealing complementary synthetic oligonucleotides jf092616.9 encoding positive-strand bases 1 to 43
and jf092616.10 representing negative-strand bases 66 to 19 of a 66-bp sequence encoding the 3FLAG
peptide (DYKDHDGDYKDHDIDYKDDDDK).
To generate plasmid pFLAG3-STh, in which the 3FLAG-encoding sequence was inserted between
the STh signal peptide and the STh propeptide, primers jf101916.33/jf092616.4 were ﬁrst used to amplify
the nucleotides (1 to 63) of estH encoding the signal peptide. Next, primers jf092616.1/jf092616.2 were
used to amplify the 3FLAG fragment from the above-described synthetic oligonucleotide 3FLAG
template ﬂanked by nucleotide extensions representing nucleotides 44 to 60 and 64 to 99 of estH, while
primers jf092616.3/jf101916.34 were used to amplify the 3= end of estH from nucleotide 64 to the native
stop codon. The three fragments were fused in a single PCR using primers jf101916.33/jf101916.34. Next,
the vector backbone was ampliﬁed using primers jf101916.31/jf101916.32 from pFLAG-CTC (Sigma),
followed by the ﬁnal assembly of pFLAG3-STh by CPEC. Similarly, to make plasmid pSTh-FLAG3, primers
jf092616.5/jf101916.35 were used to amplify 3FLAG with a 5= nucleotide extension representing
nucleotides 197 to 216 of estH, while primers jf101916.33/jf092616.8 were used to amplify the estH gene
with a 5= nucleotide extension corresponding to pFLAG-CTC. The resulting amplicons were then fused
in a single PCR using primers jf101916.33/jf101916.35 and assembled with the pFLAG-CTC backbone by
CPEC.
Cloning, expression, and puriﬁcation of recombinant ST proteins peptides. To construct a
GST-STh or mutant GST-mSTh (A14Q) expression plasmid, synthetic oligonucleotides that encompassed
the region of the estH gene corresponding to the mature peptide minus the native start codon, preceded
by an in-frame ﬂexible linker sequence (60), were synthesized (IDT, Coralville, IA). The forward sequence
(jf042715.1 for STh and jf042517.1 for mSTh), preceded by a BamHI overhang sequence (GATCC), and the
reverse sequence (jf042715.2 for STh and jf042517.2 for mSTh), preceded by an EcoRI overhang sequence
(AATTC), were mixed in a 1:1 molar ratio, heated to 95°C for 5 min, and cooled to room temperature. The
annealed double-stranded 91-bp DNA fragments were then cloned directly into the pGEX-4T1 vector
digested with BamHI and EcoRI, yielding plasmids pCW002 and pYZ011, respectively. A similar strategy
was to construct a GST-STp expression plasmid using forward oligonucleotide jf031915.5 and the reverse
sequence jf031915.6, resulting in plasmid pCW003. E. coli TOP10(pCW002), TOP10(pCW003), and
TOP10(pYZ011) were then used to express recombinant GST-STh, GST-STp, and GST-mSTh, and the
resulting fusion proteins were puriﬁed by afﬁnity chromatography. In brief, the bacterial cultures were
grown in Luria broth at 37°C to an optical density at 600 nm (OD600) between 0.6 and 0.7 and induced
with 1 mM (ﬁnal concentration) IPTG (isopropyl--D-thiogalactopyranoside) for 1 to 3 h. The cell pellets
were resuspended in 30 ml cold phosphate-buffered saline (PBS) containing 5 mM dithiothreitol (DTT),
1 protease inhibitor tablet (Roche), and 0.1 mg/ml lysozyme. Following sonication, supernatants were
clariﬁed by centrifugation at 12,000 rpm for 20 min at 4°C, followed by passage through a 0.45-m ﬁlter.
Filtered supernatants were then loaded onto columns (glutathione Sepharose High Performance; GE
Healthcare) preequilibrated with PBS, pH 7.3 (140 mM NaCl, 2.7 mM KCl,10 mM Na2HPO4, 1.8 mM KH2PO4
[pH 7.3]). After washing with 20 column volumes of PBS containing 1 mM DTT, GST fusion proteins were
eluted in fresh buffer containing 100 mM Tris-HCl (pH 8.0) and 10 mM reduced glutathione and dialyzed
against PBS.
To liberate native STh or mutant STh (mSTh) from its GST fusion partner, GST-fusion protein was
dialyzed in 50 mM NH4HCO3 (pH 8.5) containing 1 unit of thrombin (Sigma) per mg GST-fusion protein
at 4°C overnight, centrifuged at 4,000  g for 20 min with a 10-kDa-molecular-weight cutoff (MWCO)
centrifugal ﬁlter to collect the ﬁltrate, and dried by vacuum centrifugation. Peptide concentrations were
then determined by measurement of the molar extinction coefﬁcient at 280 nm (Take3; BioTek).
Transcriptional analysis of estH, estP, and tolC genes. To assess transcription of toxin genes in
mutant strains relative to wild-type H10407, the bacteria were grown overnight in 2-ml cultures of
lysogeny broth at 37°C and 225 rpm and then diluted 1:100 into fresh medium and grown for an
additional 3 h. To assess modulation of transcription upon cell contact, conﬂuent T84 cells were inﬂected
with early-log-phase H10407 bacteria (109 CFU) for 30 or 90 min. Total RNA was isolated from adherent
and planktonic (nonadherent) bacterial fractions using an RNAspin Mini isolation kit (25050070; GE Life
Sciences) and treated with DNase I (18068015; Thermo Fisher). PCR for the arcA housekeeping gene was
used to conﬁrm the removal of DNA. Total RNA was reverse transcribed (SuperScript VILO cDNA synthesis
kit, 11754250; Thermo Fisher). RNA transcripts were quantiﬁed by real-time (RT) PCR (Fast SYBR green
master mix, number 4385612 from Thermo Fisher; ViiA 7 real-time PCR system from Applied Biosystems).
Primers speciﬁc to the arcA, estH, estP, and tolC genes are listed in Table 2. All transcripts were normalized
to arcA and are presented as a ratio of transcripts in adherent bacteria relative to transcripts in planktonic
bacteria.
Production and puriﬁcation of anti-ST polyclonal antibody. To generate rabbit polyclonal anti-
body that recognizes STh, New Zealand White rabbits were immunized (Rockland) with recombinant
GST-STh. We used lyophilized E. coli AAEC191A (61) and an immobilized E. coli lysate column (44938;
Pierce) to adsorb E. coli-reactive antibodies, followed by protein G column puriﬁcation (HiTrap, GE17-
0404-01). IgG GST-STh antibodies were afﬁnity puriﬁed using GST-STh immobilized on nitrocellulose as
previously described, and anti-GST-reactive antibodies were removed by cross-adsorption against GST
coupled to glutathione agarose resin (G-250-100; Gold Biotechnology, St. Louis, MO).
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TABLE 2 Primers used in this study
Primer Sequence (5=–3=)a Description
jf070212.1 ATGAAAAAATCAATATTATTTATTTTTCTTTCTGTAGTGTAGGCTGGAGCTGCTTCG Forward primer for amplifying estH ﬂanking
from pKD13
jf070212.2 TTAATAGCACCCGGTACAAGCAGGATTACAACACAAATTCCGGGGATCCGTCGACC Reverse primer for amplifying estH ﬂanking
from pKD13
jf070212.3 ATGAAAAAGCTAATGTTGGCAATTTTTATTTCTGTAGTGTAGGCTGGAGCTGCTTC Forward primer for amplifying estP ﬂanking
from pKD13
jf070212.4 TTAATAACATCCAGCACAGGCAGGATTACAACAAAGATTCCGGGGATCCGTCGACC Reverse primer for amplifying estP ﬂanking
from pKD13
jf071612.1 GGCGCACACAAATATAAAG 368-bp amplicon in H10407-estH
downstream primer
jf071612.2 AGCGGAGAGTATAGTATGA estH upstream
jf071612.3 AAAACCAGATAGCCAGAC 168 bp upstream from estP on H10407
plasmid p666
k2 CGG TGC CCT GAA TGA ACT GC Primer binding Kmr cassette for conﬁrming
estP and tolC deletion
jf072312.1 ATGAAAAAATCAATATTATTTATTTTTCTTTCTGTACCCTGTTATCCCTAGATTT Forward primer for amplifying estH from
pGPS4
jf072312.2 TTAATAGCACCCGGTACAAGCAGGATTACAACACAATAACGGTCCTAAGGTAGC Reverse primer for amplifying estH from
pGPS4
jf072412.5 GGCCTCTTGCGGGATATCTAAATGAAAAAATCAATATTA pACYC184_ECORV_TAA_STh forward primer
for in-fusion cloning
jf072412.6 GTCGGAATGGACGATATCTTAATAGCACCCGGTACA pACYC184_ECORV_TAA_STh reverse primer
for in-fusion cloning
jf060614.2 AGGAGATATACCATGGATGAAAAAATCAATATTA Forward primer for STh in NcoI and EcoRI
sites on pETDuet-1 vector
jf060614.3 CGCCGAGCTCGAATTCTTAATAGCACCCGGTACA Reverse primer for STh in NcoI and EcoRI
sites on pETDuet-1 vector
jf060614.4 TACATATGGCAGATCTATGAAAAAGCTAATGTTG Forward primer for STp in BglII and XhoI
sites on pETDuet-1 vector
jf060614.5 CTTTACCAGACTCGAGTTAATAACATCCAGCACA Reverse primer for STp in BglII and XhoI
sites on pETDuet-1 vector
jf042715.1 GATCCGATCCCCGGGTACCGAGCTCGAATAGTAGCAATTACTGCTGTGAATTGTG
TTGTAATCCTGCTTGTACCGGGTGCTATTGAG




















3=-Mature estP gene with linker, gene,
EcoRI
jf021915.1 CGCTTACAGACAAGCTGTG Reverse sequencing primer that binds 70
bp downstream of the pGEX cloning site
jf021915.2 CCAGCAAGTATATAGCATGG Forward sequencing primer that binds 117
bp upstream of pGEX cloning site
jf110716.38 CGGGCGCAGTCTGTTCTATTG Forward primer for amplifying 1,027-bp
left-ﬂank segment of H10407 tolC
jf110716.43 TCATTTGCATTCCTTGTGGTGAAGCAGTATTTAGCGC Reverse primer for amplifying 1,027-bp left-
ﬂank segment of H10407 tolC
jf110716.44 AAAGGGTTATGTGTAGGCTGGAGCTGCTTCG Reverse primer for amplifying Kmr cassette
from strain JQ5503-1
jf110716.45 CTTCACCACAAGGAATGCAAATGATTCCGGGGATCC Forward primer for amplifying Kmr cassette
from strain JQ5503-1
jf110716.39 CTTTTCAACCTGGGCGAGGG Reverse primer for amplifying 985-bp right-
ﬂank segment of H10407 tolC
jf110716.46 CCTACACATAACCCTTTCCGTAACTGATGACGACGACGGGGCTTCGG Forward primer for amplifying 985-bp
right-ﬂank segment of H10407 tolC
jf101716.21 CGATCGTGATGCTGCCTTTG 603-bp amplicon in H10407-tolC forward
primer
jf101716.22 AGCGACAGGTTGCGTTTTTC 603-bp amplicon in H10407-tolC
downstream primer
(Continued on next page)
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Anti-STp antibody was puriﬁed from rabbit antisera (provided by Weiping Zhang, Kansas State
University) by cross-adsorption against an immobilized E. coli lysate column, which was followed by
afﬁnity puriﬁcation against recombinant GST-STp immobilized on nitrocellulose membranes for afﬁnity
puriﬁcation.
Immunoprecipitation and detection of heat-stable toxins in culture supernatants. Puriﬁed
anti-STh polyclonal IgG was immobilized with AminoLink Plus coupling resin (Pierce Direct IP kit, 26148;
Thermo Scientiﬁc). Clariﬁed culture supernatants of overnight cultures of ETEC were mixed with protease
inhibitor cocktail (88666; Thermo Fisher) and ﬁltered through a 0.45-m ﬁlter. Sixty milliliters of
supernatant was then ﬁltered through a 10-kDa-molecular-weight-cutoff membrane (Amicon). Filtrates
were then dried by vacuum centrifugation and dialyzed in PBS against a 1-kDa-cutoff membrane
(Float-A-Lyzer G2, MWCO 0.5 to 1 kDa; Spectrum Labs). Immunoprecipitations were conducted by
incubation of ﬁltrates with anti-STh-immobilized resin for 2 h at room temperature followed by elution
with 4.5% acetic acid. Eluates were dried by vacuum centrifugation and reconstituted in PBS. Immuno-
precipitated samples or puriﬁed protein/peptide as controls were applied directly to 0.22-m-pore-size
polyvinylidene diﬂuoride (PVDF) membranes (Bio-Rad) and detected by anti-STh and/or anti-STp primary
antibody and anti-rabbit horseradish peroxidase (HRP)-conjugated secondary antibody using Clarity
Western ECL substrate (Bio-Rad).
FLAG-STh fusion peptides were prepared from strain jf2847 carrying pFLAG3-STh, pSTh-FLAG3, or the
blank vector pFLAG-CTC. Brieﬂy, following overnight growth at 37°C in lysogeny broth containing
ampicillin (100 g/ml), cultures were diluted 1:100 in fresh medium, grown to an OD600 of0.2, and then
induced with 1 mM IPTG for 7 h. Forty milliliters of clariﬁed supernatant was mixed with 200 l of
anti-FLAG (M2) afﬁnity gel (A2220; Sigma), and then the mixture was incubated overnight at 4°C with
TABLE 2 (Continued)
Primer Sequence (5=–3=)a Description
jf112016.50 ATTTGCCATTGCTCACCAATAAAC Forward primer binding 2 kb upstream of
H10407 tolC
jf112016.51 CTTGCAGACTGTTAAACTGGTCG Reverse primer binding 2 kb downstream
of H10407 tolC
jf120716.52 GAACAAAAACTCATCTCAGAAGAGGATCTGAATAGCG Forward primer to amplify 4,036 bp of
pBAD/myc-His B
jf120716.53 GGTTAATTCCTCCTGTTAGCCCAAAAAACGG Reverse primer to amplify 4,036 bp of
pBAD/myc-His B
jf120716.59 GGCTAACAGGAGGAATTAACCATGCAAATGAAGAAATTGCTCCCCATTCT Forward primer H10407 tolC gene
jf120716.60 CTCTTCTGAGATGAGTTTTTGTTCTCAGTTACGGAAAGGGTTATGACCGTTACT Reverse primer H10407 tolC gene
jf092616.1 TTTCACCTTTCGCTCAGGATTACAAAGACCAC Forward bp 44–60 of estH-5=3FLAG
jf092616.2 GAAGACCCTGCTGGTTTAGCCTTGTCATCGTC Reverse bp 83–64 of estH-3=3FLAG
jf092616.3 GCTAAACCAGCAGGGTCTTCAAAAGAAAAAATTACA Forward primer bp 64–99 of estH
jf092616.4 ATCCTGAGCGAAAGGTGAAAAAGATAATACAGAAAGA Reverse primer bp 63–27 of estH
jf092616.5 CTGCTTGTACCGGGTGCTATGATTACAAAGAC Forward primer bp 197–216 of estH-5=
3FLAG
jf092616.8 ATAGCACCCGGTACAAGCAGGATTACA Reverse primer representing bp 216–190 of
estH
jf092616.9 GATTACAAAGACCACGATGGTGACTATAAAGACCATGATATCG Base pairs 1–43 and 66 through 19 of the
3FLAG-encoding sequencejf092616.10 CTTGTCATCGTCGTCTTTATAATCGATATCATGGTCTTTATAGTCACC
jf101916.31 CAGATCTGGTACCCGGGAATTCT For amplifying pFLAG-CTC vector backbone
jf101916.32 TGAAGATCGATCTCTCGATCGAGTGA
jf101916.33 ATTCCCGGGTACCAGATCTGATGAAAAAATCAATATTATTTATTTTTCTTTCTGTATT Forward primer beginning with pﬂag-CTC-
sequence followed by estH sequence bp
1–38
jf101916.34 GATCGAGAGATCGATCTTCATTAATAGCACCCGGTACAAGCAGG Reverse primer beginning with pﬂag-CTC
sequence followed by 3=estH native
reverse sequence (bp 219–196)
jf101916.35 GATCGAGAGATCGATCTTCATTACTTGTCATCGTCGTCTTTATAATCGATATCATG Reverse primer beginning with pﬂag-CTC-
sequence followed by bases 69–34 of
the 3FLAG sequence
jf092313.5 TCTTTCCCCTCTTTTAGTCAG estP RT-PCR forward primer
jf092313.6 ACAGGCAGGATTACAACAAAG estP RT-PCR reverse primer
jf092313.7 TACAAGCAGGATTACAACAC estH RT-PCR forward primer
jf092313.8 AGTGGTCCTGAAAGCATG estH RT-PCR reverse primer
jf092210.1 ATCAATCTGCCGGGTAAGAACGGT arcA RT-PCR forward primer
jf092210.2 TCCAGATCACCGCAGAAGCGATAA arcA RT-PCR reverse primer
jf030316.3 TGGATGCGAGCTCGAGCATGAAAAAGCTAATGTTG estP forward primer for pBAD/mycHisA-STp
cloning
jf060614.1 AGCTGCAGATCTCGAGTTAATAACATCCAGCACA estP reverse primer for pBAD/mycHisA-STp
cloning
aSee “Description” column for explanation of underlined bases.
Zhu et al. Infection and Immunity












agitation. After washing with Tris-buffered saline (TBS) buffer, bound proteins were eluted with 0.1 M
glycine–HCl, pH 3.5, separated by SDS-PAGE, transferred to nitrocellulose for subsequent immunoblot-
ting, and detected by anti-FLAG antibody (F1804; Sigma).
Confocal immunoﬂuorescence imaging and quantiﬁcation. To examine the delivery of FLAG-
tagged STh toxin to intestinal epithelial cells, estP estHmutant strains with or without plasmids encoding
FLAG-tagged STh were grown overnight and diluted 1:50 in CAYE-ST medium, grown to an OD600 of
0.2, and then induced with 1 mM IPTG for 2 h. The bacteria were added to T84 cells at a multiplicity
of infection (MOI) of 1:50, maintaining the induction with 1 mM IPTG. After infection with the bacteria,
T84 cells were washed with PBS, ﬁxed with 4% paraformaldehyde for 10 min at room temperature,
permeabilized with 0.1% Triton X-100 for 5 min, and blocked with 1.5% bovine serum albumin (BSA)–PBS
at 37°C for 1 h. Anti-O78 rabbit polyclonal antiserum (Penn State University) diluted 1:300 in PBS with
0.02% Tween 20 (PBST) and 1.5% BSA was used to identify H10407 and monoclonal anti-FLAG M2
antibody (number F1804; Sigma) diluted 1:500 in PBST with 1.5% BSA to detect FLAG-tagged STh.
Following incubation overnight at 4°C, slides were washed 3 times with PBS and incubated for 1 h at 37°C
with goat-anti-rabbit IgG (H&L) Alexa Fluor 488 conjugate (A11070; Thermo Fisher) and goat-anti-mouse
IgG (H&L) conjugated to Alexa Fluor 594 (A11032; Thermo Fisher) at a dilution of 1:500 in PBST containing
1.5% BSA. After washing, DAPI (4=,6-diamidino-2-phenylindole) was added at 1:6,000. Confocal micros-
copy images were acquired using a Nikon C2 confocal microscope system. To quantitate binding of
FLAG-epitope-tagged STh molecules, ﬂuorescence detection was normalized to the DAPI signal using
NIS-Elements DUO software (v4.4).
In vitro assessment of toxin delivery. Cultures of bacteria were grown overnight in lysogeny broth
from frozen glycerol stocks in CAYE-ST medium. Phosphodiesterase inhibitors (PDE-I) vardenaﬁl hydro-
chloride trihydrate (number Y0001647), rolipram (number R6520), and cilostazol (number C0737) (all
from Sigma-Aldrich) were each added to target intestinal epithelial cells at a ﬁnal concentration of 16.7
or 50 M and incubated with cells for 1.5 h (T84 cells) or 2 h (enteroids). Bacteria or toxin was added to
T84 monolayers seeded into 96-well plates, and the treatment was continued for the indicated duration.
After washing in PBS, cyclic GMP (cGMP) levels were determined by enzyme immunoassay (EIA; K020-H1;
Arbor Assays) using the acetylated protocol as directed by the manufacturer.
To examine the capacity of antibodies to neutralize ST delivery, antibody against STh and/or EtpA
was added directly to T84 cell monolayers at the indicated dilution at the time of infection. After 1.5 h,
cells were washed by PBS and lysed, and cGMP assays were performed as described above.
Growth and differentiation of T84 cells and small intestinal enteroids. T84 intestinal epithelial
cells (ATCC CCL-248) were cultured in 96-well plates for 24 to 48 h at 37°C, 5% CO2 incubator, to 90%
conﬂuence in a 1:1 mixture of Dulbecco’s modiﬁed Eagle medium (DMEM)/F12 medium supplemented with
L-glutamine (2.5mM) and fetal bovine serum (FBS; 5% [vol/vol]). Enteroids were grown as previously described
in detail (62, 63). Brieﬂy, cells obtained from the Washington University Digestive Diseases Research Core
Center BioSpecimens Core were propagated in Matrigel (BD Biosciences, San Jose, CA) in 24-well plates at
37°C with a 1:1 mixture of L-WRN (Wnt3a, R-spondin, and Noggin) conditioned medium (CM) and primary
culture medium (Advanced DEM/F12; Invitrogen) supplemented with 20% FBS, 2 mM L-glutamine, 100
units/ml penicillin, 0.1 mg/ml streptomycin, 10 M Y-27632 (ROCK inhibitor; Tocris Bioscience, R and D
Systems, Minneapolis, MN), and 10 M SB 431542 (TGFBR1 inhibitor; Tocris Bioscience, R and D Systems). Cells
were then added to Transwell ﬁlters (Corning) and incubated in differentiation medium (1:20 mixture of
L-WRN CM and primary culturemedium) lacking SB 431542 andwere grown 2 to 3 days until conﬂuence. Prior
to addition of bacteria, cells were switched to differentiation medium lacking antibiotics.
Accession number(s). Plasmids pCW002, pCW003, and pYZ011 have been deposited in Addgene
(https://www.addgene.org/) under accession numbers 90225, 90226, and 110570, respectively.
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